QOL Locally Advanced Prostate & Hyperthermia/RTx

A prospective quality of life study in patients with locally advanced prostate cancer, treated with radiotherapy with or without regional or interstitial hyperthermia

M. Van Vulpen A1, J. R. J. De Leeuw A2, M. P. R. Van Gellekom A1, J. Van Der Hoeven A3, A. De Graeff A4, R. J. A. Van Moorselaar A3, I. Van Der Tweel A5, P. Hofman A1, J. J. W. Lagendijk A1, J. J. Battermann A1

A1 Department of Radiation Oncology, University Medical Center Utrecht, Q00.118, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands A2 Department of Research Group Psychology of Health and Illness, University Medical Center Utrecht, Q00.118, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands A3 Department of Urology, University Medical Center Utrecht, Q00.118, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands A4 Department of Internal Medicine, University Medical Center Utrecht, Q00.118, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands A5 Center for Biostatistics, Utrecht University, Padualaan 14, 3584 CH, Utrecht, The Netherlands

Abstract:

Introduction: The aim of this prospective study was to describe quality of life (QoL) in patients with locally advanced prostate carcinoma treated with conventional radiotherapy and to evaluate the influence of adding regional or interstitial hyperthermia.

Materials and methods: All patients were irradiated using a CT-planned conventional three field technique, administering 70 Gy to prostate and vesicles. In two different phase I studies, hyperthermia was added to the radiotherapy.

Twelve patients were treated with one interstitial hyperthermia treatment, lasting 60 min. Fourteen patients have been treated with five regional hyperthermia treatments, lasting 75 min each. In both hyperthermia studies, the body, bladder and rectum temperatures remained below safety limits.

Patients treated with radiotherapy alone (n = 58) or combined with regional (n = 8) or interstitial hyperthermia (n = 12) completed the European Organization for Research and Treatment of Cancer (EORTC) core questionnaire (C30 + 3), the EORTC prostate cancer module (PR25) and the Rand 36 health survey before treatment and 1 and 6 months after completion of treatment.

Analysis of Variance (ANOVA) for repeated measurements has been performed to describe the data.

Results: All patient groups were comparable concerning patient characteristics. No significant interaction or difference in QoL has been noticed between the two hyperthermia patient groups and the patient group without hyperthermia.

Therefore, all groups were analysed together (n = 78) to detect QoL changes in time. A deterioration of QoL has been measured from baseline to 1 month after treatment. Fatigue, pain, urinary symptoms, bowel symptoms and financial difficulties increased significantly.

Social, physical and role functioning worsened significantly. No differences in QoL were measured 6 months after treatment compared to the baseline measurement, except for a decrease in sexual activity.

Conclusions: After radiotherapy with or without hyperthermia only a temporary deterioration of QoL occurs, concerning social, psychological and disease related symptoms.

Additional hyperthermia does not seem to decrease QoL.

International Journal of Hyperthermia

Volume 19, Number 4 / July 2003 402 - 413


Interstitial Microwave Thermal Therapy & Recurrent Prostate Ca

Intl J Hyperthermia, 11/04


Remember we are NOT Doctors and have NO medical training.

This site is like an Encyclopedia - there are many pages, many links on many topics.

Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.